Danaher Corporation $DHR Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lowered its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 0.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 968,982 shares of the conglomerate's stock after selling 4,704 shares during the quarter. California State Teachers Retirement System owned approximately 0.14% of Danaher worth $184,571,691 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Main Street Group LTD acquired a new position in Danaher during the first quarter worth about $25,000. N.E.W. Advisory Services LLC purchased a new position in shares of Danaher in the second quarter worth approximately $25,000. Hilton Head Capital Partners LLC purchased a new stake in Danaher during the fourth quarter valued at $27,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate's stock worth $29,000 after buying an additional 53 shares during the period. Finally, Evolution Wealth Management Inc. boosted its holdings in Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock worth $29,000 after buying an additional 104 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent analyst reports. TD Cowen decreased their price target on shares of Danaher from $240.00 to $236.00 and set a "buy" rating on the stock in a report on Wednesday, July 22nd. Royal Bank Of Canada boosted their target price on shares of Danaher from $200.00 to $215.00 and gave the stock an "outperform" rating in a report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. Wolfe Research cut shares of Danaher from an "outperform" rating to a "peer perform" rating in a research report on Monday, June 1st. Finally, Piper Sandler assumed coverage on shares of Danaher in a research note on Thursday, June 11th. They set a "neutral" rating and a $200.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $228.91.

Danaher Stock Up 2.4%

Shares of Danaher stock traded up $4.92 during trading on Tuesday, hitting $208.17. 2,020,860 shares of the stock traded hands, compared to its average volume of 4,423,873. The stock has a market cap of $146.34 billion, a P/E ratio of 36.97, a PEG ratio of 2.49 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a fifty day moving average price of $202.85 and a two-hundred day moving average price of $191.91. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm's quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 earnings per share. Equities research analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company's portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.